Innovative leukaemia treatment with tcxpress platform

By Taylor Mixides (Drug Target Review)2023-09-07T14:32:25

BlueSphere Bio's TCXpress platform revolutionises the isolation and functional characterisation of T-cell receptors (TCRs) with unparalleled speed and efficiency, enabling rapid identification of unique TCRs from thousands of individual T cells within days.

Already a member? Sign in

Unlock

Intelligence for the future of drug discovery

By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.

Become a member to continue reading

By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:

Unlimited access to industry intelligence that can make a difference to your business
A weekly newsletter keeping the most vital information at the front of your thinking
Exclusive invitations to powerful webinars and events featuring high profile experts
Access to deep-dive reports and analysis that reveal exciting new opportunities for business growth and transformation

Become a member